GLP-1 RAs held therapeutic potential for KOA patients with obesity or diabetes, but current evidence remained insufficient, warranting further high-quality RCTs and mechanistic studies to confirm their efficacy and safety. This evidence concerns the gene GLP1R and diabetes mellitus.